瑞格列奈 T1088

Product Introduction
Bioactivity


英文名: Repaglinide

描述: Repaglinide (AG-EE 623ZW) 是一种能够用于2 型糖尿病的胰岛素促分泌剂。

体外活性: 在喂食和饥饿的正常大鼠中,Repaglinide比给予降血糖磺脲类药物后更大更快速地增加血浆胰岛素浓度和较早地下降血糖.

体内活性: Repaglinide以钙依赖方式结合NCS蛋白质,但不与CAM或S100蛋白结合。Repaglinide以钙依赖方式紧密结合CCaMK和PpCaMK,拮抗结构域的调节功能,对CCaMK和PpCaMK域的IC 50值为55 mM和4 mM。Repaglinide以低亲和力（K（D）= 59 nM）结合单独的SUR1,但以高亲和力结合SUR1与Kir6.2共表达,增加了大约150倍。Repaglinide在视紫红质激酶测定中,拮抗恢复蛋白的抑制作用,IC50值为400 mM。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: Ethanol : 84 mg/mL (185.6 mM)
DMSO : 55 mg/mL (121.52 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)


关键字: mellitus. | Repaglinide | inhibit | Inhibitor | benzoic | type-2 | insulin | secretagogue | CMBA | diabetes | acid | carbamoylmethyl

相关产品: VU0134992 hydrochloride | Apamin acetate | Cholesterol myristate | DMP-543 | Tolbutamide | Isokaempferide | Phe-Met-Arg-Phe, amide acetate | VU0810464 | XE991 | Loureirin B

相关库: Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | Approved Drug Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | Lipid Metabolism Compound Library | EMA Approved Drug Library | Metabolism Compound Library

瑞格列奈 T1088信息由TargetMol中国为您提供，如您想了解更多关于瑞格列奈 T1088报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途